Patients with polycythemia vera (PV) fall on a spectrum of risk for thrombotic events, which can be one of the factors that ...
In estimating the burden of disease that is associated with patients at high risk of DVT or PE, health care providers and managed-care organizations should consider the entire continuum of care ...
Researchers at 37 sites in South Korea have found patients taking clopidogrel after percutaneous coronary intervention (PCI) ...
News Medical on MSN1mon
Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safetyThe COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...
In subsequent animals, the addition of 100 units/kg heparin immediately before the antibody (days 0 and 2) reduced the incidence of thrombotic complications to just two (one renal artery ...
Kristof Vercruysse, Chief Executive Officer and co-founder of TargED, said: “The dosing of the first participant with our lead compound TGD001 marks a watershed in the treatment of thrombotic ...
About Bioxodes Bioxodes is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, ...
with their burden often extending to longer-term complications such as event recurrence and post-thrombotic syndrome (PTS). Few data exist on the overall economic burden of DVT and PE and their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback